Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Device and method for simulating pharmacokinetics characteristics in vitro

A technology of kinetic characteristics and in vitro simulation, applied in teaching models, educational tools, instruments, etc., can solve the problems of less research on pharmacokinetic changes, no examination of component ratios, doses, and prescription screening issues, and achieve Plasma drug concentration and pharmacokinetic characteristic parameters are stable, well controllable, and easy to study the effect

Inactive Publication Date: 2013-04-10
SHANGHAI INST OF MATERIA MEDICA CHINESE ACAD OF SCI
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] At present, the research on combination / combination drug is mostly devoted to the investigation of pharmacodynamic indicators in clinical cases, but there are few studies on the pharmacokinetic changes of each component after combination drug and single drug
The pharmacokinetic study of a small number of multi-component combination administration is also based on the static in vitro evaluation model of drug interaction, without examining the ratio, dosage and prescription screening of each component

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Device and method for simulating pharmacokinetics characteristics in vitro
  • Device and method for simulating pharmacokinetics characteristics in vitro
  • Device and method for simulating pharmacokinetics characteristics in vitro

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0117] Example 1: In vitro pharmacokinetic simulation of single-compartment model drug and single-compartment model drug combination

[0118] The pharmacokinetics of fluorouracil and uracil conform to the single-compartment model, and the blood drug concentrations of each of them injected separately are shown in Table 1.

[0119] Table 1

[0120]

[0121] In order to obtain from the device of the present invention a combined administration mixed solution of 1 times the dose of fluorouracil administered alone and 0.5 times the dose of uracil administered alone, the specific implementation methods are:

[0122] 1) Prepare a fluorouracil stock solution with 3 times the maximum concentration of fluorouracil, that is, 28.3×3=84.9 μg / mL fluorouracil solution;

[0123] 2) Prepare a fluorouracil stock solution of 0.5 times the maximum concentration of uracil, that is, 30.9 / 2×3=46.5 μg / mL uracil solution;

[0124] 3) Blank solution: water.

[0125] 4) The maximum delivery rate of...

Embodiment 2

[0130] Example 2: In vitro pharmacokinetic simulation of the combination of a single-compartment model drug and a dual-compartment model drug

[0131] The pharmacokinetics of fluorouracil conforms to the characteristics of a one-compartment model when administered by injection, and the pharmacokinetics of methotrexate conforms to the characteristics of a two-compartment model when administered by injection.

[0132] table 3

[0133]

[0134] In order to obtain a combined administration mixed solution of 1 times the individual dosage of fluorouracil and 1 times the individual dosage of methotrexate from the device of the present invention, the specific implementation method is:

[0135] 1) Prepare a fluorouracil stock solution with 3 times the maximum concentration of fluorouracil, that is, 28.3×3=84.9 μg / mL fluorouracil solution;

[0136]2) Prepare a stock solution of methotrexate with 3 times the maximum concentration of methotrexate, i.e. 150×3=450 μg / mL uracil solution;...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a device and a method for simulating pharmacokinetics characteristics in vitro during multi-component combined administration. The device consists of a multielement variable speed liquid conveying unit, a mixing unit, a simulation unit and a detection unit, wherein the characteristics of a conveying speed-time curve of stock solution of each component are consistent with the characteristics of a blood concentration-time curve of the component in a human body or an animal body; and when the conveying velocity of the stock solution of each component is smaller than the maximum conveying velocity, the difference is supplemented by using blank solution to ensure that the sum of the sum of the input velocity of stock solution of each component and the velocity of the blank solution is in the constant state. Through the system and the method, the pharmacokinetics characteristics of the human body and the animal body can be simulated in vitro during multi-component combined administration.

Description

technical field [0001] The present invention relates to a device and method for simulating pharmacokinetic characteristics in vitro, especially an experimental device and method for simulating pharmacokinetic characteristics of multi-component combination administration in human body or animal in vitro. The multivariate variable-speed liquid delivery unit makes the concentration dynamic change characteristics of the output multi-component solution conform to the characteristics of the human or animal blood drug concentration curve after administration, so as to realize the in vitro simulation of the pharmacokinetic characteristics of the multi-component. Background technique [0002] When combined / combined medication, the metabolic kinetic process and parameters (such as absorption, distribution, metabolism and excretion, etc.) of the drug will change, mainly manifested as: [0003] Effects on drug absorption: Changes in the pH value of the digestive juice directly affect th...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): G09B23/28
Inventor 张继稳李海燕朱滨孙悦郭涛殷宪振
Owner SHANGHAI INST OF MATERIA MEDICA CHINESE ACAD OF SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com